Table 3.
Odds Ratio Estimates of the Association Between Selected Polymorphisms and Risk of Colorectal Cancer Among Clinic-Based Families in the Colon Cancer Family Registry, 1997–2007
| Gene-rsID | Nucleotide Substitution | Amino Acid Substitution | CRC vs. No CRC |
CRC vs. Neither CRC Nor Detected Polyp, Adjusted for Sex and Agea |
CRC or Detected Polyp vs. Neither, Adjusted for Sex and Ageb |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted for Sex and Agec |
Adjusted for Sex, Age, and Polypsd |
Adjusted for Sex, Age, Polyps, and Colonoscopyd |
||||||||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||
| MTHFR-rs1801133e | 677C>T | V222A | 0.81 | 0.55, 1.37 | 0.70 | 0.42, 1.15 | 0.67 | 0.40, 1.11 | 1.08 | 0.53, 2.21 | 1.15 | 0.72, 1.82 |
| MTHFR-rs1801131e | 1298C>T | A429E | 0.87 | 0.50, 1.51 | 0.91 | 0.52, 1.59 | 0.91 | 0.52, 1.59 | 0.60 | 0.33, 1.10 | 0.65 | 0.40, 1.05 |
| MTR-rs1805087e | 2756A>G | D919G | 1.00 | 0.30, 3.38 | 0.82 | 0.25, 2.75 | 0.82 | 0.25, 2.74 | 2.39 | 0.86, 6.61 | 1.64 | 0.83, 3.25 |
| MTRR-rs1801394f | 66A>G | I22M | 0.76 | 0.54, 1.08 | 0.70 | 0.49, 1.00 | 0.70 | 0.49, 1.00 | 0.88 | 0.58, 1.33 | 0.96 | 0.71, 1.30 |
| CBS-rs234706f | 699C>T | Y233Y | 1.10 | 0.79, 1.53 | 1.17 | 0.83, 1.65 | 1.18 | 0.84, 1.67 | 1.07 | 0.75, 1.54 | 1.07 | 0.83, 1.38 |
| SLC19A1-rs1051266e | 80G>A | R27H | 1.13 | 0.75, 1.69 | 1.09 | 0.72, 1.64 | 1.11 | 0.73, 1.67 | 1.11 | 0.71, 1.75 | 1.03 | 0.74, 1.45 |
Abbreviations: CBS, cystathionine-β-synthase gene; CI, confidence interval; CRC, colorectal cancer; MTHFR, methylenetetrahydrofolate reductase gene; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase gene; MTRR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase gene; OR, odds ratio; rsID, related sequence identifier; SLC19A1, solute carrier family 19 (folate transporter), member 1, gene.
a Strategy 3: n (total) = 2,173; 924 discordant sibships; 953 cases of CRC, 1,220 controls (no CRC or polyps).
b Strategy 4: n (total) = 2,736; 968 discordant sibships; 1,233 cases of CRC or polyps, 1,503 controls (no CRC or polyps).
c Strategy 1: n (total) = 2,935; 1,186 discordant sibships; 1,237 cases of CRC, 1,698 controls (no CRC).
d Strategy 2: n (total) = 2,935; 1,186 discordant sibships; 1,237 cases of CRC, 1,698 controls (no CRC). Adjusted for 1) sex, age, and polyps detected prior to baseline or 2) sex, age, polyps detected prior to baseline, and at least 1 screening colonoscopy prior to baseline.
e Recessive model.
f Dominant model.